L
Laura Colombo
Researcher at Mario Negri Institute for Pharmacological Research
Publications - 116
Citations - 4780
Laura Colombo is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Amyloid & Medicine. The author has an hindex of 34, co-authored 105 publications receiving 4196 citations. Previous affiliations of Laura Colombo include University of Siena.
Papers
More filters
Journal ArticleDOI
Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein
Claudia Balducci,Marten Beeg,Matteo Stravalaci,Antonio Bastone,Alessandra Sclip,Emiliano Biasini,Laura Tapella,Laura Colombo,Claudia Manzoni,Tiziana Borsello,Roberto Chiesa,Marco Gobbi,Mario Salmona,Gianluigi Forloni +13 more
TL;DR: It is reported that, in mice, acute intracerebroventricular injections of synthetic Aβ1–42 oligomers impaired consolidation of the long-term recognition memory, whereas mature Aβ 1–42 fibrils and freshly dissolved peptide did not, and it was confirmed that A β1– 42 oligomers interact with PrPC, with nanomolar affinity.
Journal ArticleDOI
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis.
Giuseppe Di Fede,Marcella Catania,Michela Morbin,Giacomina Rossi,Silvia Suardi,Giulia Mazzoleni,Marco Merlin,Anna Rita Giovagnoli,Sara Prioni,Alessandra Erbetta,Chiara Falcone,Marco Gobbi,Laura Colombo,Antonio Bastone,Marten Beeg,Claudia Manzoni,Bruna Francescucci,Alberto Spagnoli,Laura Cantù,Elena Del Favero,Efrat Levy,Mario Salmona,Fabrizio Tagliavini +22 more
TL;DR: An APP mutation that causes disease only in the homozygous state, whereas heterozygous carriers were unaffected, consistent with a recessive Mendelian trait of inheritance is found, with implications for genetic screening and the potential treatment of Alzheimer's disease.
Journal ArticleDOI
Anti-amyloidogenic activity of tetracyclines: studies in vitro
TL;DR: The results indicate that drugs with a well‐known clinical profile, including activity in the central nervous system, are potentially useful for Alzheimer's therapy.
Journal ArticleDOI
The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by α-synuclein or amyloid-β (1-42) peptide
Diego Albani,Letizia Polito,Sara Batelli,Stefania De Mauro,Claudia Fracasso,Giuliana Martelli,Laura Colombo,Claudia Manzoni,Mario Salmona,Silvio Caccia,Alessandro Negro,Gianluigi Forloni +11 more
TL;DR: SIRT1 activation by RES can prevent in the neuroblastoma model the deleterious effects triggered by oxidative stress or α‐syn(A30P) aggregation, while RES displayed a SIRT1‐independent protective action against Aβ42.
Journal ArticleDOI
Evaluation of Quinacrine Treatment for Prion Diseases
Agnès Barret,Fabrizio Tagliavini,Gianluigi Forloni,Clive Bate,Mario Salmona,Laura Colombo,A. De Luigi,Lucia Limido,Silvia Suardi,Giacomina Rossi,Frédéric Auvré,Karim Tarik Adjou,Nicole Salès,Alun Williams,Corinne Ida Lasmézas,Jean-Philippe Deslys +15 more
TL;DR: Despite its ability to cross the blood-brain barrier, the use of quinacrine for the treatment of CJD is questionable, at least as a monotherapy, and the multistep experimental approach employed here could be used to test new therapeutic regimes before their use in human trials.